{"id":1705,"date":"2023-09-29T16:28:22","date_gmt":"2023-09-29T21:28:22","guid":{"rendered":"https:\/\/reports.rsjh.ca\/2022\/?page_id=1705"},"modified":"2024-10-02T12:18:49","modified_gmt":"2024-10-02T17:18:49","slug":"insight-medbotics","status":"publish","type":"page","link":"https:\/\/reports.rsjh.ca\/2023\/innovation\/insight-medbotics\/","title":{"rendered":"Fusing Robotics and MRI"},"content":{"rendered":"<p>[vc_row][vc_column][vc_empty_space height=&#8221;24&#8243;]<h2 id=\"et-animated-title-1\" class=\"et-animated-title et-clearfix  curtain curtain-left\" data-mobile-font=\"inherit\" data-tablet-font=\"inherit\" data-delay=\"0\" style=\"font-weight:700;color:#212121;\"><span class=\"text-wrapper\"><span class=\"text\">Insight Medbotics Announces World\u2019s First FDA-Cleared, MRI-Compatible Robot<\/span><span class=\"curtain\" style=\"background-color:#fd8c40;\"><\/span><\/span><\/h2>[vc_empty_space][vc_column_text]<strong>Insight Medbotics, a medical device company combining the accuracy of MRI with the precision of robotics, announced a successful 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the IGAR system, the company\u2019s MRI-compatible robot. The clearance applies to breast biopsy indications.<\/strong><\/p>\n<p>IGAR is the first and only robotics system designed to work inside an MRI bore to achieve this regulatory clearance. The MRI suite is among the most challenging hospital environments because the MRI device uses strong magnetic fields and has a confined working area for physicians. The IGAR technology platform may be adapted for future products that could move seamlessly across different care environments, such as from an MRI to a standard operating room or into a physician\u2019s office.<\/p>\n<p>Insight Medbotics has demonstrated IGAR\u2019s safety and efficacy through published clinical studies in breast biopsy. The technology\u2019s other possible applications include targeting other organs and disease indications, along with therapeutic delivery and device placement.[\/vc_column_text][\/vc_column][\/vc_row][vc_row gap=&#8221;64&#8243;][vc_column width=&#8221;1\/2&#8243;]<div class=\"et-braket-block-wrapper\"><style>#et-braket-block-1 .braket-title {font-weight:700;color:#212121;}#et-braket-block-1 .braket-sub-title {color:#9a9a9a;}#et-braket-block-1 .braket-button {color:#212121 !important;}#et-braket-block-1 .braket-button:hover {color:#ffffff !important;}#et-braket-block-1 .braket-button:before {box-shadow:inset 0 0 0 1px #212121;}#et-braket-block-1 .braket-button:after {background-color:#fd8c40;}#et-braket-block-1 .braket > div:first-child,\r\n\t\t\t\t\t\t#et-braket-block-1 .braket > div:last-child,\r\n\t\t\t\t\t\t#et-braket-block-1 .braket > div:nth-child(2) > span  {background-color:#fd8c40;}<\/style><div id=\"et-braket-block-1\" data-delay=\"0\" class=\"et-braket-block right \"><div class=\"braket-block-inner et-clearfix\"><div class=\"braket\"><div><\/div><div><span><\/span><\/div><div><\/div><\/div><div class=\"braket-block-content\"><p class=\"braket-sub-title\">Fazila Seker, CEO, Insight Medbotics<\/p><h5 class=\"braket-title\" data-mobile-font=\"inherit\" data-tablet-font=\"inherit\">\u201cOur team has long believed in the untapped potential of accessible MRI imaging, artificial intelligence and robotics together to improve quality of life for patients. Many teams are researching viable paths to take robotics into the MRI suite, but IGAR is the first to secure FDA clearance. This regulatory achievement advances our long-term vision, and our commitment to delivering technology that supports the future of precision medicine.\u201d<\/h5><\/div><\/div><div class=\"braket-block-content text et-clearfix\"><\/div><\/div><\/div>[\/vc_column][vc_column width=&#8221;1\/2&#8243;][vc_column_text]The IGAR system is the brainchild of a unique combination of world-class experts in surgery and robotics. Its story begins with Professor Mehran Anvari, a surgical robotics pioneer and the scientific director and CEO of the Centre for Surgical Invention and Innovation (CSii). His team funded the preliminary human trials for IGAR, collaborating with world-leading robotics engineers from MDA\u2014Canada\u2019s leading space company\u2014to create and test the device\u2019s first prototypes. MDA is known worldwide as the designer and manufacturer of the Canadarm family of space robotics.<\/p>\n<div class=\"page\" title=\"Page 1\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Insight Medbotics was subsequently launched as a start-up company by CSii and MDA. The company also received significant funding to develop its technology\u2014including product prototype and clinical testing via CSii and the Canadian Government\u2019s Network of Centres of Excellence (NCE) program.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_empty_space height=&#8221;10px&#8221;][\/vc_column][\/vc_row][vc_row full_width=&#8221;stretch_row_content&#8221; full_height=&#8221;yes&#8221; parallax=&#8221;true&#8221; parallax_image=&#8221;1991&#8243;][vc_column][vc_empty_space height=&#8221;750&#8243;][\/vc_column][\/vc_row][vc_row][vc_column][vc_column_text]<\/p>\n<p style=\"font-weight: 400;\">\u201cFDA clearance brings this technology one crucial step closer to patients,\u201d says Anvari, who is also the founding director of both the Centre for Minimal Access Surgery and the McMaster Institute for Surgical Invention, Innovation, and Education. \u201cMcMaster University and St. Joseph\u2019s Healthcare Hamilton have been significant partners in this journey. Their 20-year investment in IGAR\u2019s research concepts, early development, and patents\u2014combined with MDA\u2019s work in space robotics\u2014made it possible to create a robot that operates safely and effectively within the extreme environment of an MRI\u2019s magnetic field.\u201d<\/p>\n<p>With the 510(k) clearance secured, Insight Medbotics will continue to advance IGAR to market.<\/p>\n<p>\u201cOur vision is to build robotics systems that make it easier to provide more targeted care everywhere,\u201d says Seker. \u201cWith this milestone, we\u2019re one step closer to making a difference in patients\u2019 lives.\u201d[\/vc_column_text][vc_empty_space height=&#8221;10px&#8221;][\/vc_column][\/vc_row][vc_row gap=&#8221;80&#8243;][vc_column width=&#8221;1\/4&#8243;][vc_single_image image=&#8221;137&#8243; img_size=&#8221;full&#8221; alignment=&#8221;center&#8221;][\/vc_column][vc_column width=&#8221;1\/4&#8243;][vc_single_image image=&#8221;1992&#8243; img_size=&#8221;full&#8221; alignment=&#8221;center&#8221;][\/vc_column][vc_column width=&#8221;1\/4&#8243;][vc_single_image image=&#8221;1993&#8243; img_size=&#8221;full&#8221; alignment=&#8221;center&#8221;][\/vc_column][vc_column width=&#8221;1\/4&#8243;][vc_single_image image=&#8221;1987&#8243; img_size=&#8221;full&#8221; alignment=&#8221;center&#8221;][\/vc_column][\/vc_row][vc_row][vc_column][vc_separator][vc_empty_space height=&#8221;24px&#8221;][vc_column_text]<\/p>\n<p style=\"font-weight: 400;\"><span class=\"TextRun Highlight SCXW219312134 BCX4\" lang=\"EN-US\" xml:lang=\"EN-US\" data-contrast=\"none\"><strong><span class=\"NormalTextRun SCXW219312134 BCX4\" data-ccp-parastyle=\"Normal (Web)\">Over the next three to five years<\/span><span class=\"NormalTextRun SCXW219312134 BCX4\" data-ccp-parastyle=\"Normal (Web)\">, Insight <\/span><span class=\"NormalTextRun SpellingErrorV2Themed SCXW219312134 BCX4\" data-ccp-parastyle=\"Normal (Web)\">Medbotics<\/span><span class=\"NormalTextRun SCXW219312134 BCX4\" data-ccp-parastyle=\"Normal (Web)\"> plans to <\/span><span class=\"NormalTextRun SCXW219312134 BCX4\" data-ccp-parastyle=\"Normal (Web)\">utilize<\/span><span class=\"NormalTextRun SCXW219312134 BCX4\" data-ccp-parastyle=\"Normal (Web)\"> the IGAR<\/span><span class=\"NormalTextRun SCXW219312134 BCX4\" data-ccp-parastyle=\"Normal (Web)\">\u2019s <\/span><span class=\"NormalTextRun SCXW219312134 BCX4\" data-ccp-parastyle=\"Normal (Web)\">1mm<\/span><span class=\"NormalTextRun SCXW219312134 BCX4\" data-ccp-parastyle=\"Normal (Web)\"> accuracy and automation as they move into advancing <\/span><\/strong><span class=\"NormalTextRun SCXW219312134 BCX4\" data-ccp-parastyle=\"Normal (Web)\"><strong>prostate cancer care.<\/strong> Insight Medbotics is aiming to reduce complications associated with traditional methods of diagnosing prostate cancer, which can require multiple random biopsies and the insertion of an ultrasound probe into the patient\u2019s rectum. <\/span><span class=\"NormalTextRun SCXW219312134 BCX4\" data-ccp-parastyle=\"Normal (Web)\">With the IGAR system, physicians can detect prostate cancer earlier and <\/span><span class=\"NormalTextRun SCXW219312134 BCX4\" data-ccp-parastyle=\"Normal (Web)\">target it with confidence, enhancing the quality of patient treatment.<\/span><\/span><span class=\"EOP SCXW219312134 BCX4\" data-ccp-props=\"{&quot;134233117&quot;:false,&quot;134233118&quot;:true,&quot;201341983&quot;:0,&quot;335557856&quot;:16777215,&quot;335559738&quot;:0,&quot;335559739&quot;:160,&quot;335559740&quot;:240}\">\u00a0<\/span><\/p>\n<p>[\/vc_column_text][\/vc_column][\/vc_row][vc_row][vc_column][vc_separator][vc_empty_space height=&#8221;24&#8243;]<h4 id=\"et-animated-title-2\" class=\"et-animated-title et-clearfix  curtain curtain-left\" data-mobile-font=\"inherit\" data-tablet-font=\"inherit\" data-delay=\"0\" style=\"font-weight:700;color:#212121;\"><span class=\"text-wrapper\"><span class=\"text\">About Insight Medbotics<\/span><span class=\"curtain\" style=\"background-color:#fd8c40;\"><\/span><\/span><\/h4>[vc_empty_space height=&#8221;12&#8243;][\/vc_column][\/vc_row][vc_row][vc_column width=&#8221;2\/3&#8243;][vc_column_text]Insight Medbotics is developing MRI-guided robotics to advance its technology to procedures where accuracy and precision matter most to patients, physicians, and hospitals. The IGAR system has been clinically demonstrated in breast cancer patients and is the world\u2019s first and only FDA-cleared, MRI-compatible robot. With a FDA 510(k) clearance in breast biopsy, Insight Medbotics envisions development in other biopsies, therapy delivery, and device placement. Learn more at <a href=\"https:\/\/insightmedbotics.com\/\">insightmedbotics.com<\/a>.[\/vc_column_text][\/vc_column][vc_column width=&#8221;1\/3&#8243;][vc_single_image image=&#8221;1979&#8243; img_size=&#8221;full&#8221; alignment=&#8221;center&#8221;][\/vc_column][\/vc_row][vc_row][vc_column][vc_empty_space height=&#8221;12&#8243;][vc_separator][vc_empty_space height=&#8221;24&#8243;][vc_icon icon_fontawesome=&#8221;far fa-lightbulb&#8221; color=&#8221;custom&#8221; size=&#8221;xl&#8221; align=&#8221;center&#8221; custom_color=&#8221;#fd8c40&#8243; link=&#8221;url:%2F2023%2Finnovation%2F|title:Innovation%20at%20St.%20Joe&#8217;s&#8221;][vc_column_text]<\/p>\n<p style=\"text-align: center;\"><a href=\"\/2023\/innovation\/\"><em>Return to Innovation at St. Joe&#8217;s<\/em><\/a><\/p>\n<p>[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>[vc_row][vc_column][vc_empty_space height=&#8221;24&#8243;][vc_empty_space][vc_column_text]Insight Medbotics, a medical device company combining the accuracy of MRI with the precision of robotics, announced a successful 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the IGAR system, the company\u2019s MRI-compatible robot. The clearance applies to breast biopsy indications. IGAR is the first and only robotics system designed to [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"parent":73,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"page-vc.php","meta":{"om_disable_all_campaigns":false,"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"_uf_show_specific_survey":0,"_uf_disable_surveys":false,"footnotes":""},"class_list":["post-1705","page","type-page","status-publish","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/reports.rsjh.ca\/2023\/wp-json\/wp\/v2\/pages\/1705","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/reports.rsjh.ca\/2023\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/reports.rsjh.ca\/2023\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/reports.rsjh.ca\/2023\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/reports.rsjh.ca\/2023\/wp-json\/wp\/v2\/comments?post=1705"}],"version-history":[{"count":6,"href":"https:\/\/reports.rsjh.ca\/2023\/wp-json\/wp\/v2\/pages\/1705\/revisions"}],"predecessor-version":[{"id":1996,"href":"https:\/\/reports.rsjh.ca\/2023\/wp-json\/wp\/v2\/pages\/1705\/revisions\/1996"}],"up":[{"embeddable":true,"href":"https:\/\/reports.rsjh.ca\/2023\/wp-json\/wp\/v2\/pages\/73"}],"wp:attachment":[{"href":"https:\/\/reports.rsjh.ca\/2023\/wp-json\/wp\/v2\/media?parent=1705"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}